Arcus Biosciences, Inc. Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
Arcus Biosciences, Inc. (RCUS) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $62.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2021-11-08
- 2021-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $62.00K.
- 2021-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $50.00K.
- 2021-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $56.00K.
- 2020-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $57.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2021-09-30 | $62.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $50.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $56.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $57.00K 10-Q · filed 2021-11-08 |
| 2020-09-30 | $87.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $151.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $315.00K 10-Q · filed 2020-05-05 |
| 2019-12-31 | $67.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $54.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $111.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $32.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |